{"nct_id": "NCT03286634", "age": "Adults", "cancer_center_accrual_goal_upper": 0, "data_table4": "Interventional", "drug_list": {"drug": [{"drug_name": "Drug: Daunorubicin"}, {"drug_name": "Drug: Epirubicin"}, {"drug_name": "Drug: 6-Mercaptopurine"}, {"drug_name": "Drug: Prednisolone"}, {"drug_name": "Drug: Methotrexate"}, {"drug_name": "Drug: Vincristine"}, {"drug_name": "Drug: Hydrocortisone"}, {"drug_name": "Drug: Cytarabine"}, {"drug_name": "Drug: Cyclophosphamide"}, {"drug_name": "Drug: E-coli L-asparaginase"}]}, "long_title": "Asia-wide, Multicenter Open-label, Phase II Non-randomised Study Involving Children With Down Syndrome Under 21 Year-old With Newly Diagnosed, Treatment na\u00efve Acute Lymphoblastic Leukemia", "management_group_list": {"management_group": [{"is_primary": "Y", "management_group_name": "Group1"}]}, "oncology_group_list": {"oncology_group": [{"group_name": "Group1", "is_primary": "N"}]}, "phase": "PHASE2", "principal_investigator": "", "principal_investigator_institution": "National Hospital Organization Nagoya Medical Center", "program_area_list": {"program_area": [{"is_primary": "Y", "program_area_name": "Program1"}]}, "protocol_id": 0, "protocol_no": "", "protocol_target_accrual": 60, "protocol_type": "INTERVENTIONAL", "prior_treatment_requirements": ["Inclusion Criteria:", "* Down syndrome diagnosed clinically or cytogenetically (including Mosaic Down)", "* Newly diagnosed ALL according to WHO 2016 classification.", "* Age \\< 21 years old at time of enrollment.", "* ECOG performance status (PS) score of 0-2.", "* Written informed consent obtained from legally acceptable representatives.", "Exclude - Exclusion Criteria:", "Exclude - * Second malignancy.", "Exclude - * Philadelphia positive ALL.", "Exclude - * Mature B-ALL.", "Exclude - * Mixed phenotype acute leukemia.", "Exclude - * Any previous treatment with cytotoxic chemotherapy excluding treatment for TAM or radiation therapy. Patient pre-treated with short term steroid (\\< 7 days of duration within last 1 month prior to treatment start) can be enrolled into this study.", "Exclude - * Renal dysfunction with creatinine \\>2x upper limit of normal (ULN). Patients whose creatinine has improved to \\<2x ULN before treatment commencement can enrol subject to discretion of site PI.", "Exclude - * Liver dysfunction with direct bilirubin \\> 5x ULN.", "Exclude - * Any serious uncontrolled medical condition or impending end organ dysfunction that would impair the ability of the subject to receive protocol therapy, including:", "Exclude - 1. History of coronary arterial disease, cardiomyopathy, heart failure, arrhythmia (other than sinus arrhythmia) or severe cardiac malformation which with residual abnormalities or requires further major corrective surgery within 2 years.", "Exclude - 2. Ongoing uncontrolled hypertension.", "Exclude - 3. Ongoing uncontrolled diabetes mellitus.", "Exclude - 4. Ongoing uncontrolled infection.", "Exclude - 5. History of congenital or acquired immunodeficiency including HIV infection.", "Exclude - 6. History of interstitial pneumonia, pulmonary fibrosis, bronchiectasis or severe pulmonary emphysema.", "Exclude - 7. CNS hemorrhage.", "Exclude - 8. Psychiatric disorder.", "Exclude - 9. Other concurrent active neoplasms.", "Exclude - * Pregnant or lactating women.", "Exclude - * Doubtful compliance or ability to complete study therapy due to financial, social, familial or geographic reason, or in the judgement of site investigator."], "short_title": "ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016", "site_list": {"site": []}, "sponsor_list": {"sponsor": [{"is_principal_sponsor": "Y", "sponsor_name": "National Hospital Organization Nagoya Medical Center", "sponsor_protocol_no": "", "sponsor_roles": "sponsor"}]}, "staff_list": {"protocol_staff": []}, "status": "open to accrual", "summary": "To evaluate the outcome of a prednisolone and low dose methotrexate based protocol in Down syndrome children with ALL (DS-ALL) in an Asia-wide study. The treatment protocol was modified based upon backbone of Taiwan Pediatric Oncology Group (TPOG)-ALL protocol in which risk classification will be guided by level of flow minimal residual disease (MRD) instead.", "treatment_list": {"step": [{"arm": [{"arm_code": "SR", "arm_internal_id": 0, "arm_description": "Standard Risk (SR) :\n\nCNS 3 or CNS 2 regardless of response OR Time-point #1 (Day 15 induction) Flow MRD \u2265 1% (treatment will not be de-escalated even MRD \\<0.01% by TP#2) OR Time-point #2 (Day 1 IDMTX/MP of Consolidation) \u22650.01%\n\nSR strategy:\n\nAll SR patient will have to receive two doses of anthracycline and 12 L-asparaginase doses during induction except those who are escalated to SR at time point 2 when MRD \u22650.01%.\n\nDuring the first year of maintenance phase (48 weeks; 4x12 weeks blocks), cyclophosphamide and cytarabine bolus will be administered at 4 weekly interval.", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Daunorubicin", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Prednisolone", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Drug: Vincristine", "level_internal_id": 2, "level_suspended": "N"}, {"level_code": "3", "level_description": "Drug: Epirubicin", "level_internal_id": 3, "level_suspended": "N"}, {"level_code": "4", "level_description": "Drug: E-coli L-asparaginase", "level_internal_id": 4, "level_suspended": "N"}, {"level_code": "5", "level_description": "Drug: 6-Mercaptopurine", "level_internal_id": 5, "level_suspended": "N"}, {"level_code": "6", "level_description": "Drug: Methotrexate", "level_internal_id": 6, "level_suspended": "N"}, {"level_code": "7", "level_description": "Drug: Hydrocortisone", "level_internal_id": 7, "level_suspended": "N"}, {"level_code": "8", "level_description": "Drug: Cytarabine", "level_internal_id": 8, "level_suspended": "N"}, {"level_code": "9", "level_description": "Drug: Cyclophosphamide", "level_internal_id": 9, "level_suspended": "N"}]}, {"arm_code": "LR", "arm_internal_id": 1, "arm_description": "Low Risk (LR):\n\nTime-point #1 (Day 15 induction) Flow MRD \\<1% AND Time-point #2 (Day 1 IDMTX/MP of Consolidation) \\<0.01% AND CNS 1 only\n\nLR strategy:\n\nFor LR patients, one dose of anthracycline and 3 doses of L-asparaginase will be omitted during induction.\n\nFollowing re-induction I, interim maintenance and additional block of re-induction ie. re-induction II prior to maintenance phase will be omitted for LR patients.", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Daunorubicin", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Prednisolone", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Drug: Vincristine", "level_internal_id": 2, "level_suspended": "N"}, {"level_code": "3", "level_description": "Drug: Epirubicin", "level_internal_id": 3, "level_suspended": "N"}, {"level_code": "4", "level_description": "Drug: E-coli L-asparaginase", "level_internal_id": 4, "level_suspended": "N"}, {"level_code": "5", "level_description": "Drug: 6-Mercaptopurine", "level_internal_id": 5, "level_suspended": "N"}, {"level_code": "6", "level_description": "Drug: Methotrexate", "level_internal_id": 6, "level_suspended": "N"}, {"level_code": "7", "level_description": "Drug: Hydrocortisone", "level_internal_id": 7, "level_suspended": "N"}]}], "match": [{"and": [{"clinical": {"oncotree_primary_diagnosis": "", "disease_status": ["", ""]}}, {"genomic": {"hugo_symbol": "", "variant_category": ""}}]}]}]}}